Sweden's Camurus Q1 revenue misses; reiterates 2026 financial outlook

Camurus AB

12/05/2026 06:08

Overview

Sweden biopharma firm's Q1 revenue fell 5% and missed analyst expectations

Product sales dropped 12% while royalties rose 44% in the quarter

Company reiterated 2026 financial outlook and awaits FDA decision on Oclaiz in June

Outlook

Camurus reiterates its 2026 financial outlook

Company expects FDA decision on Oclaiz in US on 10 June 2026

Camurus plans to share Phase 3 SORENTO study results after completing randomized part

Result Drivers

UK DISTRIBUTION MODEL - Co said sales revenues recovered after changes to UK distribution model in Q4 2025

ROYALTY GROWTH - Royalties increased 44% in the quarter

Company press release: ID:nWkr5xNwXQ

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Miss
SEK 533 mln
SEK 665.25 mln (4 Analysts)
Q1 EBIT
SEK 168 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for Camurus AB is SEK780.00, about 43.1% above its May 11 closing price of SEK545.00

The stock recently traded at 27 times the next 12-month earnings vs. a P/E of 33 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)